# Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

> **NCT07092410** · PHASE4 · WITHDRAWN · sponsor: **SRH Wald-Klinikum Gera GmbH**

## Conditions studied

- Melanoma BRAF V600E/K Mutated

## Interventions

- **DRUG:** Encorafenib & Binimetinib Treatment

## Key facts

- **NCT ID:** NCT07092410
- **Lead sponsor:** SRH Wald-Klinikum Gera GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-08
- **Primary completion:** 2030-08
- **Final completion:** 2030-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated early due to insufficient patient recruitment.
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07092410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07092410, "Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07092410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*